U.S., Sept. 17 -- ClinicalTrials.gov registry received information related to the study (NCT07175493) titled 'A Study of CM336 in Patients With Relapsed or Refractory Autoimmune Cytopenia' on Aug. 29.
Brief Summary: To evaluate the efficacy and safety of CM336 (B Cell Maturation Antigen/Cluster of Differentiation 3 Bispecific Antibody) in the treatment of patients with relapsed or refractory autoimmune cytopenia
Study Start Date: Oct. 31
Study Type: INTERVENTIONAL
Condition:
Autoimmune Cytopenia
Immune Thrombocytopenia (ITP)
Autoimmune Hemolytic Anemia
Evans Syndrome
Intervention:
BIOLOGICAL: CM336 Injection
subcutaneous CM336 administration, step-up dosing, Dose and frequency of CM336 according to the protocol
Recruitment Status: ...